Talaris Therapeutics Inc TALS:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 10:06 AM EDT
15.57quote price arrow up+0.12 (+0.78%)
Volume
10,803
52 week range
11.41 - 19.82

...

Loading . . .
  • Open15.57
  • Day High15.97
  • Day Low15.46
  • Prev Close15.45
  • 52 Week High19.82
  • 52 Week High Date06/07/21
  • 52 Week Low11.41
  • 52 Week Low Date05/18/21

Key Stats

  • Market Cap643.20M
  • Shares Out41.31M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open15.57
  • Day High15.97
  • Day Low15.46
  • Prev Close15.45
  • 52 Week High19.82
  • 52 Week High Date06/07/21
  • 52 Week Low11.41
  • 52 Week Low Date05/18/21
  • Market Cap643.20M
  • Shares Out41.31M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.55
  • P/E (TTM)-28.27
  • Fwd P/E (NTM)-13.03
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Talaris Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Talaris Therapeutics, Inc. is a late-clinical stage, cell therapy company developing therapies. The Company is principally focused on developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The Company's lead product candidate, FCR001, which is central to its facilitated Allo-HSCT therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor. FCR001 is processed in the Company's good manufacturing practice...
Scott Requadt J.D.
Chief Executive Officer
Gregg Beloff J.D.
Chief Financial Officer
Roderick Purdy
Vice President
Address
201 E. Jefferson St., Suite 110B,
Louisville, KY
40202
United States